The Shanghai Forum on the Integrated Development of Science, Technology and Economy was successfully held on June 27, 2025. This forum is jointly organized by the Shanghai Association for Science and Technology and the Shanghai Society for the Integration of Science and Technology Economy (Shanghai Science and Technology Economy Association) under the guidance of the China Association for Science and Technology. It focuses on the key bottlenecks in the transformation of scientific and technological achievements and is committed to building an international platform for the integration of science and technology economy. At the forum site, the "Top Ten Innovative Cases of Integrated Development of Science and Technology and Economy in the Yangtze River Delta in 2025" were awarded. The project of Yuanwu Medical, "iPSC Technology Platform Driving the Revolution in the Treatment of Chronic Degenerative Diseases", stood out in the "field of technology Transfer" with its breakthrough original technology and was successfully selected as one of the top ten cases, demonstrating Yuanwu Medical's outstanding strength and innovative vitality in this field.

Starting from the concept of "the right cells, performing the right functions", Yuanvore Medicine has successfully prepared engineered induced cells with complete phenotypes and safe and effective effects by integrating gene editing technology, iPSC reprogramming technology and iPSC directed induction differentiation technology. This not only overcomes the problem that traditional chemical drugs cannot repair and regenerate human cell tissues, but also reduces the side effects of treatment. Achieve complete repair of organ functions and radical cure of chronic degenerative diseases. In the future, by integrating innovative technologies such as bioactive materials, 4D printing technology and organ-on-a-chip, a new type of intelligent, personalized and systematic treatment system will be constructed, promoting the leapfrog upgrade of cell therapy from "simple cell transplantation" to "structural functional reconstruction". The strong technological innovation and industry demonstration demonstrated by this project are expected to release huge economic and social benefits in the future, inject new impetus into the integrated development of science and technology and economy in the Yangtze River Delta, and also open up a brand-new and promising path for the treatment of chronic degenerative diseases. This recognition is attributed to Yuanwu Medical's reliance on the abundant university resources and top-notch research platforms in the Yangtze River Delta region, which has fully leveraged its talent advantages and greatly stimulated its innovative vitality. Meanwhile, by leveraging the industrial advantages of emerging clusters such as biomedicine, Yuanwu Medical has successfully achieved a dual breakthrough in iPSC technology research and development and the transformation of scientific and technological achievements. In the future, Yuanwu Medical will continue to focus on the core technology track of iPSC, taking innovation and breakthroughs as the engine to accelerate the value transformation of laboratory achievements into clinical applications. By iteratively upgrading more efficient cell therapy solutions, it will inject technological impetus into the cause of human chronic degenerative diseases and provide strong impetus for the integrated development of science and technology and economy in the Yangtze River Delta.

Top ten Innovative Cases of Integrated Development of Science and Technology and Economy in the Yangtze River Delta

The "Top Ten Innovative Cases of Science and Technology Economy Integration in the Yangtze River Delta" is an important event initiated by the Shanghai Society for Science and Technology Economy Integration (Shanghai Science and Technology Economy Association), focusing on the Yangtze River Delta region (Shanghai, Zhejiang, Jiangsu, and Anhui), adhering to the principles of innovation, effectiveness, and demonstration. Committed to exploring representative successful experiences in key areas such as the transformation of scientific and technological achievements, industry-university-research cooperation, scientific and technological financial services, digital transformation and innovative applications, as well as regional collaborative innovation, the top ten innovative cases of the integrated development of science and technology and economy in the Yangtze River Delta in 2025 will be ultimately selected.

Regarding Yuanvore Medicine

Shanghai Yuanvore Medicine Technology Co., Ltd. is a regenerative medicine company dedicated to the development and application of iPSC (Induced pluripotent stem Cells) technology. Founded in 2021, it has been certified as a national-level technology-based small and medium-sized enterprise. In the three key areas of cell reprogramming, directed differentiation, and cell engineering, it has applied for 37 globally leading independent intellectual property rights, including 12 invention patents. Among them, six have been authorized and two have applied for PCT, providing solutions for the application of iPSC technology in regenerative medicine to treat chronic degenerative diseases. In November 2024, a metabolic disease cooperation project was officially launched with Shanghai Sixth People's Hospital. This is also the first time that iPSC technology has been applied globally to treat such diseases. At present, the two pipelines are Parkinson's Disease (PD) and osteoarthritis (OA). The R&D proof-of-concept and preclinical animal efficacy experiments have been completed, and the CMC process development is underway. The behavioral, molecular biological tests and imaging results of animal experiments show that the engineered cell drugs based on iPSC have significant effects on both diseases. It is expected that the IIT research will be initiated and the IND submitted in 2026. "Yuan" is the initial, and one yuan gives rise to three. The earth element "Wu" is solid and heavy, and it nourishes all living things. Yuanwu Medicine, taking stem cells as the carrier, starts from the concept of "the right cells, performing the right functions", and uses small molecules to regulate cell fate. While precisely obtaining target phenotypic cells, it also increases the yield of target cells, providing industrialized regenerative medicine solutions for the treatment of chronic degenerative diseases. It will be empowered and applied in the fields of aging, degeneration, and injury in the big health sector. Create disruptive medical value and market value.